

ASSESSING THE IMPACT OF PPI DEPRESCRIPTION EDUCATION METHODS IN THE ENGLISH PRIMARY CARE NETWORK

Cathal Coyle

UEG Week Copenhagen 2023

Poster

October 15, 2023

A pilot deprescribing system deployed across 62 English surgeries identified 96.4% of 80,218 PPI patients as eligible for dose reduction or discontinuation, with pharmacist-led support achieving approximately 26% reduction in prescriptions.

KEY POINTS

- Three intervention tiers were tested: data platform with resources, platform plus online support, and platform plus pharmacist-led mentorship supporting audit.
- Among approximately 80,218 patients reviewed, 77,356 (96.4%) were identified as eligible for PPI dose reduction or deprescribing based on demographics, dosage, treatment duration and indication.
- In Tier 3 with pharmacist support, 7890 (22.85%) of approximately 34,500 patients were stepped off PPIs and 1031 (2.99%) were stepped down, representing an approximate 26% decrease in PPI prescriptions.
- The authors conclude that pharmacist-led deprescribing support in Primary Care Networks is an effective hands-on approach to reducing PPI overprescribing.
- This material is most relevant to those designing deprescribing interventions or quality improvement initiatives in primary care prescribing.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/c59e84fe-743b-11ee-a8c9-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.